168 related articles for article (PubMed ID: 21080034)
1. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.
Gong F; Peng X; Zeng Z; Yu M; Zhao Y; Tong A
Mol Cell Biochem; 2011 Feb; 348(1-2):141-7. PubMed ID: 21080034
[TBL] [Abstract][Full Text] [Related]
2. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
4. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
5. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
[TBL] [Abstract][Full Text] [Related]
6. Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline.
Zhou J; Wei YH; Liao MY; Xiong Y; Li JL; Cai HB
Asian Pac J Cancer Prev; 2012; 13(12):6435-9. PubMed ID: 23464471
[TBL] [Abstract][Full Text] [Related]
7. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds.
Guidi F; Puglia M; Gabbiani C; Landini I; Gamberi T; Fregona D; Cinellu MA; Nobili S; Mini E; Bini L; Modesti PA; Modesti A; Messori L
Mol Biosyst; 2012 Apr; 8(4):985-93. PubMed ID: 22134777
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
9. [Expression of nuclear autoantigenic sperm protein in platinum resistance ovarian cancer cell clones].
Wang HX; Tan Y
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(1):61-3. PubMed ID: 20356529
[TBL] [Abstract][Full Text] [Related]
10. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.
Stewart JJ; White JT; Yan X; Collins S; Drescher CW; Urban ND; Hood L; Lin B
Mol Cell Proteomics; 2006 Mar; 5(3):433-43. PubMed ID: 16319398
[TBL] [Abstract][Full Text] [Related]
11. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
Althurwi SI; Yu JQ; Beale P; Huq F
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
[TBL] [Abstract][Full Text] [Related]
12. The proteomic analysis of cisplatin resistance in breast cancer cells.
Smith L; Welham KJ; Watson MB; Drew PJ; Lind MJ; Cawkwell L
Oncol Res; 2007; 16(11):497-506. PubMed ID: 18306929
[TBL] [Abstract][Full Text] [Related]
13. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines.
Dai Z; Yin J; He H; Li W; Hou C; Qian X; Mao N; Pan L
Proteomics; 2010 Nov; 10(21):3789-99. PubMed ID: 20957754
[TBL] [Abstract][Full Text] [Related]
15. Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.
Gray TA; MacLaine NJ; Michie CO; Bouchalova P; Murray E; Howie J; Hrstka R; Maslon MM; Nenutil R; Vojtesek B; Langdon S; Hayward L; Gourley C; Hupp TR
J Immunol Methods; 2012 Apr; 378(1-2):20-32. PubMed ID: 22361111
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
17. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
